drugset / Trial / NCT01458847
Cis-urocanic Acid (Cis-UCA) in Patients With Primary or Recurrent Non-muscle Invasive Bladder Cancer
Phase 1
Completed
12 enrolled
BioCis Pharma Ltd
FinnMedi Oy · collabTampere University Hospital · collabTurku University Hospital · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate safety, tolerability and pharmacokinetics of intravesical cis-urocanic acid in patients with primary or recurrent non-muscle invasive bladder cancer.
Timeline
- Start
- 2009-10
- Primary completion
- 2012-11
- Completion
- 2012-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | cis-urocanic acid | Small molecule | 2 % | Other |
| Subject | cis-urocanic acid | Small molecule | 4 % | Other |
| Subject | cis-urocanic acid | Small molecule | 6 % | Other |
| Subject | cis-urocanic acid | Small molecule | 50 ml | Other |